Compare Brunswick Corporation (BC) vs TG Therapeutics Inc (TGTX) Price & Performance

Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.

The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.